Holen Sie sich die Stockscreener-App
9.18
5.56%
-0.54
Handel nachbörslich:
9.18
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $15.00 at Morgan Stanley - MarketBeat
NRIX: Morgan Stanley Maintains Rating, Lowers Price Target to $1 - GuruFocus
NRIX: HC Wainwright & Co. Maintains Rating but Lowers Price Targ - GuruFocus
Using data models to predict Nurix Therapeutics Inc. stock movement2025 Price Action Summary & Consistent Profit Focused Trading Strategies - newser.com
What technical charts say about Nurix Therapeutics Inc. stockPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
Earnings visualization tools for Nurix Therapeutics Inc.2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Is Nurix Therapeutics Inc. forming a reversal patternPortfolio Gains Summary & AI Optimized Trading Strategy Guides - newser.com
Nurix Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 4.4%Should You Sell? - MarketBeat
Can Nurix Therapeutics Inc. stock hit record highs againWeekly Market Report & Weekly Top Gainers Alerts - newser.com
Will Nurix Therapeutics Inc. stock recover faster than peersTreasury Yields & AI Powered Market Entry Strategies - newser.com
Applying chart zones and confluence areas to Nurix Therapeutics Inc.2025 Fundamental Recap & Consistent Profit Alerts - newser.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - simplywall.st
Nurix Therapeutics (NRIX): Losses Worsen 21.7% Annually, Reinforcing Profitability Concerns Despite Growth Narrative - Yahoo Finance
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Down Following Weak Earnings - MarketBeat
Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results - MarketBeat
Wall Street Zen Downgrades Nurix Therapeutics (NASDAQ:NRIX) to Strong Sell - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading 8.7% HigherStill a Buy? - MarketBeat
Oppenheimer Maintains Nurix Therapeutics (NRIX) Outperform Recommendation - Nasdaq
What analysts say about Nurix Therapeutics Inc stockTake Profit Strategies & Low Cost Portfolio Ideas - earlytimes.in
Nurix Therapeutics (NRIX) Stock Falls After Q3 Earnings Miss - GuruFocus
Using portfolio simulators with Nurix Therapeutics Inc. includedOil Prices & Accurate Technical Buy Alerts - newser.com
Is Nurix Therapeutics Inc. showing signs of accumulationJuly 2025 Breakouts & Long Hold Capital Preservation Plans - newser.com
Nurix Therapeutics (NRIX) Analyst Rating Update: Piper Sandler L - GuruFocus
Detecting price anomalies in Nurix Therapeutics Inc. with AIJuly 2025 Update & Short-Term High Return Ideas - newser.com
Nurix Therapeutics (NRIX) Price Target Lowered by Oppenheimer | - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Nurix Therapeutics (NRIX) Reports Wider Q3 Earnings Miss - GuruFocus
Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday - Benzinga
Nurix Therapeutics Inc reports results for the quarter ended August 31Earnings Summary - TradingView
Nurix Therapeutics Reports Third Quarter 2025 Financial Results And Provides A Corporate Update - TradingView
Nurix Therapeutics Doubles Down On Pivotal Trials Despite Losses - Finimize
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Nurix Therapeutics Inc Reports Q3 2025 Earnings: EPS of ($1.03) Misses Estimates, Revenue at $7.9 Million Falls Short - GuruFocus
NRIX Q3 Revenue Falls Short; Future Research Endeavors Outlined - GuruFocus
Nurix Therapeutics shares tumble 9% on wider-than-expected Q3 loss, revenue miss - Investing.com Nigeria
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - The Manila Times
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q3 Revenue $7.9M, vs. FactSet Est of $16.0M - MarketScreener
How Nurix Therapeutics Inc. stock performs in weak economyQuarterly Investment Review & High Conviction Investment Ideas - newser.com
Smart tools for monitoring Nurix Therapeutics Inc.’s price action2025 Sector Review & Technical Confirmation Trade Alerts - newser.com
What MACD and RSI say about Nurix Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Does Nurix Therapeutics Inc. qualify in momentum factor screeningPortfolio Return Report & Real-Time Buy Zone Alerts - newser.com
Nurix Therapeutics Inc Stock Analysis and ForecastGlobal Trade Effects & Low Cost Market Strategies - earlytimes.in
Using Bollinger Bands to evaluate Nurix Therapeutics Inc.2025 Support & Resistance & Low Risk Entry Point Guides - newser.com
Technical analysis overview for Nurix Therapeutics Inc. stockAnalyst Downgrade & Smart Allocation Stock Tips - newser.com
Nurix Therapeutics Inc. stock trend forecastMarket Sentiment Summary & Weekly Momentum Stock Picks - newser.com
What momentum shifts mean for Nurix Therapeutics Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - newser.com
Nurix Therapeutics Inc.’s volatility index tracking explained2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):